1 |
中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 12(4): 317-318.
|
2 |
WANG L, YU W, YIN X, et al. Prevalence of osteoporosis and fracture in China: The China osteoporosis prevalence study[J]. JAMA network open, 2021, 4(8): e2121106.
|
3 |
BROWN J P, DON-WAUCHOPE A, DOUVILLE P, et al. Current use of bone turnover markers in the management of osteoporosis[J]. Clinical biochemistry, 2022, 109-110: 1-10.
|
4 |
HAUSCHKA P V. Osteocalcin: The vitamin K-dependent Ca2+-binding protein of bone matrix[J]. Haemostasis, 1986, 16(3-4): 258-272.
|
5 |
DELMAS P D. Biochemical markers of bone turnover. I: Theoretical considerations and clinical use in osteoporosis[J]. The American journal of medicine, 1993, 95(5A): 11S-16S.
|
6 |
张萌萌, 张秀珍, 邓伟民, 等. 骨代谢生化指标临床应用专家共识(2020)[J].中国骨质疏松杂志, 2020, 26(6): 781-796.
|
7 |
SHOU Z, JIN X, BIAN P, et al. Reference intervals of β-C-terminal telopeptide of type Ⅰ collagen, procollagen type Ⅰ N-terminal propeptide and osteocalcin for very elderly Chinese men[J]. Geriatrics & gerontology international, 2017, 17(5): 773-778.
|
8 |
HU W W, ZHANG Z, HE J W, et al. Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal women[J]. International journal of endocrinology, 2013, 2013: 513925.
|
9 |
中华医学会骨质疏松和骨矿盐疾病分会, 章振林. 原发性骨质疏松症诊疗指南(2022)[J].中国全科医学, 2023, 26(14): 1671-1691.
|
10 |
EASTELL R, HANNON R A. Biomarkers of bone health and osteoporosis risk[J]. The proceedings of the nutrition society, 2008, 67(2): 157-162.
|
11 |
BACHRACH L K. Acquisition of optimal bone mass in childhood and adolescence[J]. Trends in endocrinology and metabolism, 2001, 12(1): 22-28.
|
12 |
ZHANG Y, ZHANG J, HUANG X, et al. Variation of bone turnover markers in childhood and adolescence[J]. International journal of clinical practice, 2023, 2023: 5537182.
|